New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
09:21 EDTSRPTRW Baird remains bullish on Sarepta after 144 week DMD data
Baird said Sarepta's 144 week data for eteplirsen did not necessarily help reinforce its NDA filing, but the firm still thinks the drug's ability to delay disease progression is demonstrated by the data. The firm maintains its bullish view of the stock and keeps an Outperform rating and $53 price target on Sarepta.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use